e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tuberculosis: cost of illness in Germany
Diel Roland, Rutz Stefan, Castell Stefanie, Schaberg Tom
Source:
Eur Respir J 2012; 40: 143-151
Journal Issue:
July
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Diel Roland, Rutz Stefan, Castell Stefanie, Schaberg Tom. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Source: Eur Respir J 2011; 38: 516-528
Year: 2011
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Current status of fluoroquinolone use for treatment of tuberculosis in Korea
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Cost of illness of non-multidrug-resistant tuberculosis in Germany: an update
Source: ERJ Open Res, 6 (4) 00329-2020; 10.1183/23120541.00329-2020
Year: 2020
Adherence to the recommendation of prescribing 4 drugs in the intensive phase of the standard treatment of tuberculosis in Spain
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures?
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
MDR-TB guidelines: what is new on clinical management
Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management
Year: 2020
Gene-Xpert for rapid detection of MDR-TB in re-treatment cases;a comparison with standard culture and DST
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Effectiveness of mandatory treatment for tuberculosis - An observational registry study
Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Year: 2013
Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Influence of early diagnostics with Xpert MTB/RIF on MDR TB patients treatment efficacy
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Clinical profile of MDR-TB patients and their early response to DOTS PLUS: An Indian perspective
Source: Annual Congress 2013 –Tuberculosis: clinical aspects
Year: 2013
Cost-effectiveness of treating MDR-TB by adding delamanid to background regimens in Germany
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Four cases, one family: A cluster of resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia)
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014
Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe
Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept